Our study demonstrates that Lp-PLA2 activity is elevated in patients with T2DM and MASLD and is closely associated with metabolic risk factors, including dyslipidemia, insulin resistance, and metabolic syndrome. This evidence concerns the gene PLA2G7 and metabolic syndrome.